$PFE

PFIZER INC

CIK:0000078003|SEC Filings
v3.25.4
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Alliance revenues $ 9,266 $ 8,388 $ 7,582
Total revenues [1] 62,579 63,627 59,553
Costs and expenses:      
Cost of sales [2],[3] 16,067 17,851 24,954
Selling, informational and administrative expenses [2] 13,794 14,730 14,771
Research and development expenses [2] 10,437 10,822 10,679
Acquired in-process research and development expenses 1,613 108 194
Amortization of intangible assets 4,874 5,286 4,733
Restructuring charges and certain acquisition-related costs 1,550 2,419 2,943
Other (income)/deductions––net 6,724 4,388 222
Income from continuing operations before provision/(benefit) for taxes on income [4],[5],[6] 7,520 8,023 1,058
Provision/(benefit) for taxes on income (266) (28) (1,115)
Income from continuing operations 7,787 8,051 2,172
Discontinued operations––net of tax 25 11 (15)
Net income before allocation to noncontrolling interests 7,812 8,062 2,158
Less: Net income attributable to noncontrolling interests 41 31 39
Net income attributable to Pfizer Inc. common shareholders $ 7,771 $ 8,031 $ 2,119
Earnings per common share––basic:      
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) $ 1.37 $ 1.42 $ 0.38
Discontinued operations––net of tax (in dollars per share) 0 0 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) 1.37 1.42 0.38
Earnings per common share––diluted:      
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) 1.36 1.41 0.37
Discontinued operations––net of tax (in dollars per share) 0 0 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) $ 1.36 $ 1.41 $ 0.37
Weighted-average shares––basic (in shares) 5,683 5,664 5,643
Weighted-average shares––diluted (in shares) 5,713 5,700 5,709
Product [Member]      
Revenues $ 51,663 $ 53,816 $ 50,914
Royalty [Member]      
Revenues $ 1,650 $ 1,423 $ 1,058
[1] Revenues are primarily attributed to countries based on the location of the customer.
[2] Exclusive of amortization of intangible assets.
[3] See Note 17A.
[4] Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include costs related to manufacturing and supply, sales and marketing activities, R&D, and medical and safety activities that are associated with products in our Biopharma segment. Effective in the third quarter of 2025, certain expenses for corporate affairs, such as for U.S. policy and government relations, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified Selling, informational and administrative expenses of approximately $170 million and $156 million in 2024 and 2023, respectively, from Other business activities to Biopharma to conform to the current period presentation.
[5] 2024 v. 2023––The reduction in the domestic loss in 2024 versus the domestic loss in 2023 is primarily attributable to increased revenues offset by higher restructuring charges and asset impairment charges. The increase in the international income is primarily attributable to lower: Cost of Sales, Restructuring charges and certain acquisition-related costs and asset impairment charges.
[6] 2025 v. 2024––The domestic income in 2025 versus the domestic loss in 2024 is primarily attributable to a reduction in operating expenses and restructuring charges, partially offset by higher asset impairment and legal charges. The decrease in the international income in 2025 versus international income in 2024 is primarily attributable to higher asset impairment charges. For 2025, the data in this table conforms to the updated income tax disclosure guidance in accordance with ASU 2023-09.